

pharmaceutical preparation of a mono amine oxidase inhibitor hydrazide drug in an amount effective to shutdown ongoing protein biosynthesis thereby inducing apoptosis and cell replacement with new cells that are free of disease or DNA damage.

23. The method of claim 1 and 2 where said diseased cells are replaced with cancerous cells, viral infected cells, and DNA damaged cells.

24. A method for antibiotic adjuvant use comprising the administering of a pharmaceutical preparation of a mono amine oxidase inhibitor hydrazide concurrent with antibiotic therapy sufficient to render microorganisms vulnerable to antibiotic action by inhibiting microorganism protein biosynthesis of enzymes that would metabolize, detoxify, block, or repair damage done by the antibiotic action, and that likewise inhibits peptide biosynthesis used to induce cell division and growth, and hence proliferation which serves to render the microorganisms sterile and without progeny to pass on any antibiotic resistance traits that may evolve.

25. The method of claim 1, 2 and 4 where a mono amine oxidase inhibitor hydrazide drug is replaced with Iproniazid, Isocarboxazid, Nialamide, and any irreversible substrate hydrazide.

Specification: Please replace the existing Specification with the substitute Specification provided.

Remarks - General

The applicant has rewritten the Claims, the Specification, the Abstract, and the Information Disclosure Statement so that all parts of the application will be in concert toward articulating a “different purpose type claim” which the applicant believes is necessary to resolve the objections and rejections cited.